• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利妥昔单抗诱导的冠状动脉痉挛。

Rituximab-induced coronary vasospasm.

作者信息

Lee Linda, Kukreti Vishal

机构信息

Department of Oncology, Niagara Health System, St. Catharines, ON, Canada L2R 2Z7.

出版信息

Case Rep Hematol. 2012;2012:984986. doi: 10.1155/2012/984986. Epub 2012 Jun 6.

DOI:10.1155/2012/984986
PMID:22953082
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3420582/
Abstract

Rituximab has improved the treatment of B-cell non-Hodgkin lymphomas. While it is generally well tolerated, serious adverse effects including infusion reactions with hemodynamic compromise and cardiac arrhythmias or ischemia are possible. We report a case of coronary vasospasm occurring during a rituximab infusion in a patient with minimal tumour burden and who had no cardiac risk factors. This case highlights that determination of the cause of ischemia is important and may identify some patients who can be successfully rechallenged.

摘要

利妥昔单抗改善了B细胞非霍奇金淋巴瘤的治疗。虽然它通常耐受性良好，但仍可能出现严重不良反应，包括伴有血流动力学障碍、心律失常或缺血的输注反应。我们报告了1例肿瘤负荷极小且无心脏危险因素的患者在利妥昔单抗输注期间发生冠状动脉痉挛的病例。该病例强调，确定缺血原因很重要，且可能识别出一些能够成功再次接受治疗的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d892/3420582/8524fc79de28/CRIM.HEMATOLOGY2012-984986.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d892/3420582/57b676e3796d/CRIM.HEMATOLOGY2012-984986.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d892/3420582/8524fc79de28/CRIM.HEMATOLOGY2012-984986.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d892/3420582/57b676e3796d/CRIM.HEMATOLOGY2012-984986.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d892/3420582/8524fc79de28/CRIM.HEMATOLOGY2012-984986.002.jpg

相似文献

1
Rituximab-induced coronary vasospasm.利妥昔单抗诱导的冠状动脉痉挛。
Case Rep Hematol. 2012;2012:984986. doi: 10.1155/2012/984986. Epub 2012 Jun 6.
2
A case of coronary vasospasm after repeat rituximab infusion.利妥昔单抗重复输注后发生冠状动脉痉挛一例。
Case Rep Cardiol. 2015;2015:523149. doi: 10.1155/2015/523149. Epub 2015 Mar 18.
3
Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.利妥昔单抗快速输注在非霍奇金淋巴瘤和慢性淋巴细胞白血病成年患者中的急性不良反应。
JBI Libr Syst Rev. 2011;9(1):1-30. doi: 10.11124/01938924-201109010-00001.
4
Acute coronary syndromes complicating the first infusion of rituximab.首次输注利妥昔单抗并发急性冠状动脉综合征。
Clin Lymphoma Myeloma. 2008 Aug;8(4):253-5. doi: 10.3816/CLM.2008.n.035.
5
QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case.QT 延长，尖端扭转型室性心动过速，冠状动脉痉挛引起的心肌缺血和头痛药物。第 1 部分：用曲坦类药物病例回顾 5-羟色胺能心脏不良事件。
Headache. 2013 Jan;53(1):208-216. doi: 10.1111/j.1526-4610.2012.02300.x. Epub 2012 Dec 6.
6
Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.利妥昔单抗：在慢性淋巴细胞白血病、低级别或滤泡性淋巴瘤以及弥漫性大 B 细胞淋巴瘤中的应用综述。
Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000.
7
Rituximab-Induced Acute ST Elevation Myocardial Infarction.利妥昔单抗诱导的急性ST段抬高型心肌梗死
Ochsner J. 2015 Summer;15(2):187-90.
8
Cardiovascular adverse events complicating the administration of rituximab: report of two cases.利妥昔单抗给药引发的心血管不良事件：两例报告。
Tumori. 2013 Nov-Dec;99(6):288e-92e. doi: 10.1700/1390.15471.
9
A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.B细胞淋巴瘤患者中利妥昔单抗输注相关反应的临床预测模型。
Int J Clin Pharm. 2017 Apr;39(2):380-385. doi: 10.1007/s11096-017-0429-3. Epub 2017 Jan 31.
10
Infusion-related reactions to rituximab: frequency, mechanisms and predictors.利妥昔单抗相关输注反应：频率、机制和预测因素。
Expert Rev Clin Immunol. 2019 Apr;15(4):383-389. doi: 10.1080/1744666X.2019.1562905. Epub 2019 Jan 11.

引用本文的文献

1
Rituximab-Associated Acute Ischemic Stroke in a Patient With Primary Angiitis of the Central Nervous System.利妥昔单抗相关的急性缺血性卒中发生在一名患有中枢神经系统原发性血管炎的患者身上。
Cureus. 2024 Oct 14;16(10):e71412. doi: 10.7759/cureus.71412. eCollection 2024 Oct.
2
An Unusual Case of Delayed-Onset Rituximab-Induced Ventricular Tachycardia: A Case Report.利妥昔单抗诱导的迟发性室性心动过速一例报告
J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241255813. doi: 10.1177/23247096241255813.
3
Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction.

本文引用的文献

1
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.报告关键性 III 期临床试验中靶向抗癌药物的严重药物不良反应。
J Clin Oncol. 2011 Jan 10;29(2):174-85. doi: 10.1200/JCO.2010.31.9624. Epub 2010 Dec 6.
2
A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function.一项I-II期研究，旨在确定利妥昔单抗的最大耐受输注速率，特别强调监测利妥昔单抗对心脏功能的影响。
Clin Cancer Res. 2008 Dec 1;14(23):7935-9. doi: 10.1158/1078-0432.CCR-08-1124.
3
Acute coronary syndromes complicating the first infusion of rituximab.
生物制剂对心血管炎症的影响：机制洞察与风险降低
J Inflamm Res. 2021 May 14;14:1915-1931. doi: 10.2147/JIR.S282691. eCollection 2021.
4
Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.利妥昔单抗治疗膜性肾病后发生的非缺血性心肌病。
J Renal Inj Prev. 2016 Nov 2;6(1):18-25. doi: 10.15171/jrip.2017.04. eCollection 2017.
5
A case of coronary vasospasm after repeat rituximab infusion.利妥昔单抗重复输注后发生冠状动脉痉挛一例。
Case Rep Cardiol. 2015;2015:523149. doi: 10.1155/2015/523149. Epub 2015 Mar 18.
6
Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?利妥昔单抗诱发的应激性心肌病：其心脏毒性是否比表面所见更严重？
BMJ Case Rep. 2015 Mar 2;2015:bcr2014208203. doi: 10.1136/bcr-2014-208203.
首次输注利妥昔单抗并发急性冠状动脉综合征。
Clin Lymphoma Myeloma. 2008 Aug;8(4):253-5. doi: 10.3816/CLM.2008.n.035.
4
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.R-CVP与单纯环磷酰胺、长春新碱和泼尼松相比，用于既往未治疗的晚期滤泡性淋巴瘤患者的III期研究。
J Clin Oncol. 2008 Oct 1;26(28):4579-86. doi: 10.1200/JCO.2007.13.5376. Epub 2008 Jul 28.
5
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.利妥昔单抗联合一线米托蒽醌、苯丁酸氮芥和泼尼松龙化疗，随后进行干扰素维持治疗，可延长晚期滤泡性淋巴瘤患者的生存期：东德血液学和肿瘤学研究组的一项研究。
J Clin Oncol. 2007 May 20;25(15):1986-92. doi: 10.1200/JCO.2006.06.4618. Epub 2007 Apr 9.
6
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.与单纯使用环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）方案治疗相比，在CHOP方案基础上加用利妥昔单抗进行一线治疗可显著改善晚期滤泡性淋巴瘤患者的预后：德国低度淋巴瘤研究组的一项前瞻性随机研究结果。
Blood. 2005 Dec 1;106(12):3725-32. doi: 10.1182/blood-2005-01-0016. Epub 2005 Aug 25.
7
Cardiac toxicity during rituximab administration.利妥昔单抗给药期间的心脏毒性。
Leuk Lymphoma. 2004 Jan;45(1):203-4. doi: 10.1080/10428190310001607160.
8
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.5-氟尿嘧啶相关心脏毒性患者的预防措施
Br J Cancer. 2003 May 19;88(10):1507-9. doi: 10.1038/sj.bjc.6600967.
9
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.利妥昔单抗作为惰性非霍奇金淋巴瘤患者的一线及维持治疗药物
J Clin Oncol. 2002 Oct 15;20(20):4261-7. doi: 10.1200/JCO.2002.08.674.
10
Complement activation plays a key role in the side-effects of rituximab treatment.补体激活在利妥昔单抗治疗的副作用中起关键作用。
Br J Haematol. 2001 Dec;115(4):807-11. doi: 10.1046/j.1365-2141.2001.03166.x.